| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTHRC1 |
| Uniprot No | Q96CG8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-243aa |
| 氨基酸序列 | SEIPKGKQKA QLRQREVVDL YNGMCLQGPA GVPGRDGSPG ANGIPGTPGI PGRDGFKGEK GECLRESFEE SWTPNYKQCS WSSLNYGIDL GKIAECTFTK MRSNSALRVL FSGSLRLKCR NACCQRWYFT FNGAECSGPL PIEAIIYLDQ GSPEMNSTIN IHRTSSVEGL CEGIGAGLVD VAIWVGTCSD YPKGDASTGW NSVSRIIIEE LPK |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CTHRC1重组蛋白的参考文献及其摘要概括(注：文献为模拟示例，具体作者和内容需根据实际研究调整)：
---
1. **标题**: *Recombinant CTHRC1 Promotes Cell Migration in Vascular Remodeling*
**作者**: Smith A, et al.
**摘要**: 研究利用重组CTHRC1蛋白处理血管平滑肌细胞，发现其通过激活TGF-β信号通路增强细胞迁移能力，并抑制胶原沉积，提示其在血管损伤修复中的潜在作用。
2. **标题**: *CTHRC1 Recombinant Protein Suppresses Tumor Metastasis via Modulating Wnt/PCP Pathway*
**作者**: Zhang L, et al.
**摘要**: 实验表明，重组CTHRC1蛋白通过抑制Wnt/PCP通路降低癌细胞侵袭性，在黑色素瘤小鼠模型中显著减少肺转移，提示其作为抗癌治疗靶点的可能性。
3. **标题**: *Purification and Functional Analysis of Recombinant CTHRC1 in Collagen Synthesis Regulation*
**作者**: Kim Y, et al.
**摘要**: 该研究优化了CTHRC1重组蛋白的原核表达与纯化流程，并证实其通过调控胶原I/III比例抑制纤维化，为肝纤维化治疗提供了实验依据。
---
**提示**：实际文献需通过数据库(如PubMed、Web of Science)检索关键词“CTHRC1 recombinant protein”或结合具体研究领域筛选。部分研究可能侧重重组蛋白的制备，另一些则聚焦其功能机制。
CTHRC1 (Collagen Triple Helix Repeat-Containing 1) is a secreted glycoprotein implicated in diverse physiological and pathological processes, including tissue repair, fibrosis, and cancer progression. First identified in balloon-injured arteries, it is evolutionarily conserved and expressed in vertebrates. The protein is characterized by a collagen triple helix repeat domain and a C-terminal globular domain, with an N-terminal signal peptide directing its secretion. Post-translational modifications, such as glycosylation, influence its stability and interactions.
Functionally, CTHRC1 regulates extracellular matrix (ECM) remodeling by modulating collagen deposition and cell migration. It acts as a Wnt/β-catenin signaling enhancer in tissue repair, promoting cell motility while suppressing excessive fibrosis. However, in pathologies like cancer, CTHRC1 is often overexpressed in aggressive tumors (e.g., breast, pancreatic, gastric cancers), where it drives metastasis by enhancing ECM invasion, angiogenesis, and epithelial-mesenchymal transition (EMT). Its dysregulation is also linked to fibrotic disorders and osteoarthritis.
Recombinant CTHRC1 protein, produced via mammalian or bacterial expression systems, retains bioactivity for in vitro and in vivo studies. It is purified for functional assays, antibody development, and mechanistic exploration of signaling pathways. Researchers utilize it to dissect its role in tumor microenvironments, fibroblast activation, and regenerative processes. Therapeutic interest lies in targeting CTHRC1 to inhibit metastasis or modulate fibrosis, though its dual roles in repair and disease necessitate context-specific strategies.
Overall, CTHRC1 recombinant protein serves as a critical tool for unraveling its complex biology and translational potential in oncology and regenerative medicine.
×
